0001209191-20-048864.txt : 20200831
0001209191-20-048864.hdr.sgml : 20200831
20200831204114
ACCESSION NUMBER: 0001209191-20-048864
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200828
FILED AS OF DATE: 20200831
DATE AS OF CHANGE: 20200831
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Munshi Amit
CENTRAL INDEX KEY: 0001612551
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-31161
FILM NUMBER: 201153121
MAIL ADDRESS:
STREET 1: C/O EPIRUS BIOPHARMACEUTICALS, INC.
STREET 2: 699 BOYLSTON STREET, 8TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001080709
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 232908305
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-453-7200
MAIL ADDRESS:
STREET 1: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-08-28
0
0001080709
ARENA PHARMACEUTICALS INC
ARNA
0001612551
Munshi Amit
C/O ARENA PHARMACEUTICALS, INC.
6154 NANCY RIDGE DRIVE
SAN DIEGO
CA
92121
1
1
0
0
President and CEO
Common Stock
2020-08-28
4
M
0
50000
15.50
A
57750
D
Common Stock
2020-08-28
4
S
0
50000
70.00
D
7750
D
Common Stock
2020-08-31
4
M
0
50000
15.50
A
57750
D
Common Stock
2020-08-31
4
S
0
50000
70.1007
D
7750
D
Employee Stock Option (right to buy)
15.50
2020-08-28
4
M
0
50000
0.00
D
2023-05-11
Common Stock
50000
288139
D
Employee Stock Option (right to buy)
15.50
2020-08-31
4
M
0
50000
0.00
D
2023-05-11
Common Stock
50000
238139
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.50, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4.
The options vested over four years, with 25% of the shares subject to the option vesting on May 11, 2017, and the remainder of the shares vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and were exercisable once vested.
/s/ Andrew J. Cronauer, as Attorney-in-Fact
2020-08-31